智通财经APP获悉，截止7月24日收盘，有190只股票创52周新高，其中大唐西市(00620)、国药科技股份 (08156)、环联连讯(01473)创高率位于前3位，分别为41.43%、37.50%、23.64%。 | 康臣药业(01681) | 12.860 | 12.860 | 2.06% | | --- | --- | --- | --- | | 药明合联(02268) | 57.100 | 57.700 | 2.03% | | 品质国际(00243) | 0.465 | 0.510 | 2.00% | | 浙江沪杭甬(00576) | 7.650 | 7.680 | 1.99% | | ＧＸ中美科技(03402) | 72.700 | 73.100 | 1.95% | | 隽思集团(01412) | 1.550 | 1.580 | 1.94% | | 新华保险(01336) | 48.300 | 48.700 | 1.88% | | 华夏日股对冲(03160) | 23.000 | 23.080 | 1.85% | | 基石药业－Ｂ(02616) | 7.580 | 7.700 | 1.85% | | ...

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

Group 1 - As of June 3, a total of 105 stocks reached their 52-week highs, with Huayin International Holdings (00989), Dingyifeng Holdings (00612), and Youquhui Holdings (02177) leading the high rate at 57.26%, 37.93%, and 23.02% respectively [1] - The closing prices and highest prices for the top three stocks are as follows: Huayin International Holdings at 1.370 and 1.950, Dingyifeng Holdings at 0.770 and 0.800, and Youquhui Holdings at 3.550 and 3.580 [1] - Other notable stocks that reached their 52-week highs include China Antibody-B (03681) with a high rate of 21.62% and Fengcheng Holdings (02295) at 19.52% [1] Group 2 - The report also lists stocks that reached their 52-week lows, with Des Holdings (08437) showing the largest decline at -38.79%, followed by Dimi Life Holdings (01667) at -20.50% [3] - The closing prices and lowest prices for the top three stocks that reached their lows are: Des Holdings at 0.177 and 0.071, Dimi Life Holdings at 0.140 and 0.128, and Lujizhi Technology (01745) at 0.197 and 0.194 [3] - Other stocks with significant declines include GBA Group (00261) at -11.48% and Baide International (02668) at -10.88% [3]

Financial Performance - For the six months ended December 31, 2024, Sinopharm Tech Holdings Limited reported revenue of HKD 18,898,000, a slight increase from HKD 18,844,000 in the same period of 2023, representing a growth of 0.29%[5] - The gross profit for the same period was HKD 6,500,000, significantly up from HKD 3,121,000 in 2023, indicating a gross margin improvement of approximately 108.8%[5] - Operating loss increased to HKD 1,075,000 from HKD 350,000 year-over-year, reflecting a deterioration in operational efficiency[5] - The net loss attributable to shareholders for the period was HKD 5,513,000, compared to HKD 2,876,000 in 2023, representing an increase in loss of 91.0%[5] - Total comprehensive loss for the period was HKD 4,367,000, worsening from HKD 3,315,000 in the same period last year[7] - The basic loss per share for the period was HKD 0.0217, compared to HKD 0.0157 in the prior year, indicating a worsening loss per share situation[7] - The company reported a total revenue of HKD 18,844,000 from supply chain services for the six months ended December 31, 2023, with a slight increase from HKD 18,898,000 in the same period of 2024[22][28] - The group recorded unaudited consolidated revenue of HKD 18,900,000 for the year 2024, a 1% increase from HKD 18,800,000 in 2023[64] - Gross profit margin increased to approximately 34% in 2024, compared to 17% in 2023[64] - The group reported a loss attributable to shareholders of HKD 5,500,000 in 2024, compared to a loss of HKD 2,900,000 in 2023[64] Financial Position - Current liabilities amounted to HKD 63,193,000, a decrease from HKD 249,436,000 as of June 30, 2024, indicating improved liquidity management[9] - The company's total assets less current liabilities showed a net negative position of HKD 18,511,000, compared to HKD 204,946,000 previously, indicating a substantial decline in financial health[9] - Cash and cash equivalents increased to HKD 3,347,000 at the end of the reporting period, compared to HKD 8,505,000 at the end of the previous year, reflecting a decrease of 60.7%[17] - Total assets as of December 31, 2024, amounted to HKD 44,682,000, an increase from HKD 44,490,000 as of June 30, 2024[24] - The company's total liabilities increased to HKD 63,341,000 as of December 31, 2024, compared to HKD 250,089,000 as of June 30, 2024[24] - The debt-to-asset ratio improved to 12% as of December 31, 2024, down from 162% on June 30, 2024[74] Cash Flow - The company reported net cash used in operating activities of HKD (781,000) for the six months ended December 31, 2024, an improvement from HKD (1,317,000) in the same period of 2023[17] - The company reported a net cash inflow from financing activities of HKD 1,488,000, a decrease from HKD 8,271,000 in the previous year, indicating reduced financing activity[17] - The company’s operating cash flow showed a slight improvement, with cash used in operations decreasing from HKD (1,331,000) to HKD (784,000) year-over-year[17] Financing Costs - The financing costs rose to HKD 3,383,000 compared to HKD 1,889,000 in the previous year, marking an increase of 79.0%[5] - The company incurred financing costs of HKD (3,383,000) during the reporting period, contributing to the overall loss[21] - The company recorded financing costs of HKD 3,383,000 for the six months ended December 31, 2024, up from HKD 1,889,000 in the same period of 2023[31] Equity and Share Capital - The company's total equity attributable to shareholders decreased to HKD (13,919,000) as of December 31, 2024, from HKD (176,324,000) as of December 31, 2023, indicating a significant reduction in equity[14] - The company completed a capital reorganization, reducing the par value of each issued share from HKD 0.3125 to HKD 0.0125, effective November 6, 2024[81] - The company's authorized share capital remains at HKD 200,000,000, divided into 12,800,000,000 ordinary shares and 3,200,000,000 non-voting convertible preferred shares[53] Debt Management - The company issued convertible bonds with a principal amount of HKD 50,000,000 at a coupon rate of 7%[44] - The company completed a debt capitalization agreement, issuing 547,609,590 convertible preferred shares at HKD 0.1 each to offset the total debt amount[48] - The total debt reduction from the loan capitalizations is estimated to be approximately HKD 193,000,000, which will improve the company's capital structure and reduce interest burdens[109] - Following the completion of the Creative Big loan capitalization agreement, the total debt owed to Creative Big has been fully repaid, relieving the company of its obligations under this debt[119] Operational Strategy - The company plans to continue expanding its supply chain services and explore new markets as part of its growth strategy[26] - The group is focusing on expanding its supply chain services and health product distribution, aiming to enhance revenue sources and market opportunities[72] - The company aims to focus more on its business operations and seize future fundraising opportunities following the debt reduction[117] Management and Governance - The board of directors consists of executive directors Mr. Ho Kam Kin and Ms. Kwok Suk Yi; non-executive director Mr. Cheng Yan Kit; and independent non-executive directors Mr. Lau Fei, Mr. Hsu Tung An, and Mr. Cheung Pik Lun[129] - The company has complied with the GEM Listing Rules and has established an audit committee consisting of three independent non-executive directors[127] - The company has adopted the trading code of conduct as per GEM Listing Rules for directors' securities transactions, confirming compliance throughout the review period[126] Employee and Management Compensation - Short-term benefits for directors and key management personnel amounted to HKD 1,120,000 for the six months ended December 31, 2024, compared to HKD 1,367,000 for the same period in 2023[61] - The company employed 30 staff members as of December 31, 2024, down from 33 on June 30, 2024[88] Shareholder Information - As of December 31, 2024, Integrated Asset holds 321,694,520 shares, representing approximately 50.77% of the company's total shares[97] - Quantum Worldwide Investment Limited owns 150,000,000 shares, accounting for about 23.67% of the company's total shares[97] - The board of directors and key executives hold a total of 2,999,600 ordinary shares, representing approximately 0.48% of the company's issued share capital[91] Compliance and Regulatory Matters - The company has not adopted any new accounting standards that would have a significant impact on its financial reporting for the current period[19] - The company has not engaged in any arrangements that would allow directors or key executives to benefit from purchasing shares or bonds during the reporting period[95] - The company has no knowledge of any significant matters affecting the group from the end of the reporting period to the report date[62]

Financial Performance - For the six months ended December 31, 2024, the company reported revenue of HKD 18,898,000, a slight increase from HKD 18,844,000 in the same period of 2023, representing a growth of 0.29%[6] - Gross profit for the same period was HKD 6,500,000, significantly up from HKD 3,121,000, indicating a year-over-year increase of 108.83%[6] - The company incurred a loss before tax of HKD 4,458,000, compared to a loss of HKD 2,239,000 in the previous year, reflecting an increase in losses of 99.57%[6] - The basic loss per share for the period was HKD 2.17, compared to HKD 1.57 in the prior year, indicating a deterioration in earnings per share[8] - The company's total comprehensive loss for the period was HKD 4,367,000, compared to a loss of HKD 3,315,000 in the previous year, representing an increase of 31.69%[8] - For the six months ended December 31, 2024, the company reported a loss attributable to shareholders of HKD 5,513,000, compared to a loss of HKD 2,876,000 for the same period in 2023, representing an increase in loss of approximately 92%[15] - The company recorded a pre-tax loss of HKD 5,513,000 for the six months ended December 31, 2024, compared to a pre-tax loss of HKD 2,876,000 for the same period in 2023, indicating a deterioration in financial performance[38] - The group reported a loss attributable to shareholders of HKD 5,500,000 in 2024, compared to a loss of HKD 2,900,000 in 2023[65] Assets and Liabilities - Total assets as of December 31, 2024, were HKD 39,004,000, compared to HKD 38,068,000 as of June 30, 2024, showing a slight increase of 2.45%[10] - Total assets as of December 31, 2024, amounted to HKD 44,682,000, an increase from HKD 44,490,000 as of June 30, 2024, reflecting a growth of 0.43%[25] - Current liabilities totaled HKD 63,193,000, a decrease from HKD 249,436,000, indicating a reduction of 74.69%[10] - Total liabilities increased to HKD 63,341,000 as of December 31, 2024, up from HKD 50,089,000 as of June 30, 2024, representing a rise of 26.4%[25] - The company’s total liabilities to total assets ratio increased to 1.42 as of December 31, 2024, compared to 1.12 as of June 30, 2024, indicating a higher financial leverage[25] - The debt-to-asset ratio improved to 12% as of December 31, 2024, down from 162% on June 30, 2024[75] Cash Flow and Financing - Cash and cash equivalents increased to HKD 3,347,000 at the end of the reporting period, compared to HKD 8,505,000 at the end of the previous year, reflecting a decrease of approximately 60%[18] - The company generated a net cash outflow from operating activities of HKD 781,000 for the six months ended December 31, 2024, compared to HKD 1,317,000 for the same period in 2023, showing a reduction in cash burn[18] - The company incurred financing costs of HKD 3,383,000 during the reporting period, contributing to the overall loss[22] - The company reported a significant increase in financing costs to HKD 3,383,000 from HKD 1,889,000, which is an increase of 79.00%[6] - The company issued convertible preferred shares amounting to HKD 148,015,000 as part of its financing activities during the period[15] - The company issued convertible bonds amounting to HKD 50,000,000 with a coupon rate of 7%[45] Inventory and Receivables - The company's inventory increased significantly to HKD 16,546,000 from HKD 3,537,000, marking a rise of 368.73%[10] - Trade receivables amounted to HKD 15,262,000 as of December 31, 2024, down from HKD 22,442,000 as of June 30, 2024, representing a decrease of 32%[41] - Other receivables and prepayments were HKD 6,257,000 as of December 31, 2024, compared to HKD 11,859,000 as of June 30, 2024, indicating a decline of 47%[41] - Total receivables, net of provisions for bad debts, stood at HKD 19,111,000 as of December 31, 2024, down from HKD 31,891,000 as of June 30, 2024, a decrease of 40%[41] Capital Structure and Shareholder Information - The company’s total equity attributable to shareholders decreased to HKD (13,919,000) as of December 31, 2024, from HKD (172,733,000) as of December 31, 2023, indicating a significant improvement in equity position[15] - As of December 31, 2024, the total issued and paid-up capital was HKD 155,936,000, up from HKD 57,404,000 as of July 1, 2024, an increase of 171%[51] - The company has established a stock option plan as of June 9, 2021, for incentivizing employees[94] - Directors and key executives hold a total of 1,600,000 ordinary shares each, representing 0.25% of the company’s equity[92] - Integrated Asset holds 321,694,520 shares, representing approximately 50.77% of the company's total shares[98] - Quantum Worldwide Investment Limited owns 150,000,000 shares, accounting for about 23.67% of the company's total shares[98] Corporate Governance and Compliance - The company has adhered to the GEM Listing Rules and corporate governance codes, with no significant deviations reported during the review period[124] - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited results for the six months ending December 31, 2024, ensuring compliance with applicable accounting standards[128] - The board of directors consists of executive directors Mr. Ho Kam Kin and Ms. Kwok Suk Yi; non-executive director Mr. Cheng Yan Kit; and independent non-executive directors Mr. Liu Fei, Mr. Xu Dong An, and Mr. Cheung Pik Lun[130] Future Outlook and Strategic Focus - The group is focusing on expanding its supply chain services and health products, aiming to enhance its revenue sources and market opportunities[73] - The company currently has no major future investment or capital asset plans, but will continue to monitor industry conditions[88] - The company has no knowledge of any significant matters affecting the group since the end of the reporting period[63]

Financial Performance - For the six months ended December 31, 2023, the company reported revenue of HKD 18,844,000, an increase of 25.0% compared to HKD 15,025,000 for the same period in 2022[3] - The gross profit for the six months was HKD 3,121,000, reflecting a slight increase of 2.7% from HKD 3,039,000 in the previous year[3] - The company incurred a loss before tax of HKD 2,239,000 for the six months, compared to a profit of HKD 15,769,000 in the same period last year, indicating a significant decline[3] - The net loss attributable to equity holders for the six months was HKD 2,876,000, compared to a profit of HKD 15,408,000 in the prior year[3] - The company reported a basic loss per share of HKD 0.29 for the three months ended December 31, 2023, compared to earnings of HKD 6.07 per share in the same period last year[5] - The company reported a net loss of HKD 2,876,000 for the six months ended December 31, 2023, compared to a profit of HKD 15,408,000 in the same period last year, representing a significant decline[9] - The company’s total comprehensive income for the period was a loss of HKD 4,151,000, compared to a gain of HKD 13,692,000 in the same period last year[9] - The company reported a loss attributable to equity holders of HKD 2,900,000, compared to a profit of HKD 15,400,000 in the previous year[50] Assets and Liabilities - Total assets as of December 31, 2023, amounted to HKD 36,702,000, up from HKD 27,045,000 as of June 30, 2023[6] - The company's current liabilities increased to HKD 228,739,000 from HKD 213,236,000, indicating a rise in financial obligations[6] - The net liabilities of the company stood at HKD 182,509,000 as of December 31, 2023, compared to HKD 179,754,000 at the end of June 2023[8] - The total liabilities as of December 31, 2023, were HKD 228,739,000, with classified liabilities of HKD 46,296,000[17] Cash Flow and Liquidity - The company’s cash and bank balances increased to HKD 8,505,000 from HKD 1,776,000, indicating improved liquidity[6] - Total cash and cash equivalents increased to HKD 8,505,000 as of December 31, 2023, up from HKD 7,283,000 at the end of the previous year, indicating a growth of approximately 16.7%[11] - Operating cash flow for the period was a net outflow of HKD 1,317,000, a decrease from a net inflow of HKD 4,720,000 in the prior year, reflecting a change of approximately 128%[11] - The company’s cash flow from financing activities generated a net inflow of HKD 8,271,000, compared to an outflow of HKD 290,000 in the previous year[11] Revenue Segments - Revenue from the manufacturing and distribution segment amounted to HKD 18,844,000, with a segment loss of HKD 2,046,000 for the period[15] - For the six months ended December 31, 2023, the total revenue from the "Internet+" services (supply chain) was HKD 18,844,000, an increase of 74.2% compared to HKD 10,825,000 in the same period of 2022[21] - The revenue from manufacturing and distribution of personal protective equipment was HKD 4,200,000, contributing to a total revenue of HKD 18,844,000 for the period[21] - The "Internet+" service segment generated revenue of HKD 18,800,000, a 74% increase compared to the previous year[51] Financing and Capital Structure - The company incurred financing costs of HKD 1,889,000 during the reporting period, contributing to the overall loss[15] - The company has convertible bonds with a principal amount of HKD 89,625,000, with a conversion price adjusted to HKD 0.598 per share after a share split[40] - The company issued convertible bonds with a principal amount of HKD 50,000,000, maturing on February 20, 2023, with an annual interest rate of 7%[45] - The adjusted conversion price for the convertible bonds is HKD 0.221 per share, allowing for the conversion into a maximum of 405,542,986 shares[44] - As of December 31, 2023, the total outstanding balance of the convertible bonds was HKD 105,747,000, which includes the principal and accrued interest[44] - The company has a total issued and paid-up capital of HKD 57,404,000 as of December 31, 2023[47] - The company has not issued any dividends, maintaining an expected dividend yield of 0%[46] Corporate Governance - The company has adopted and complied with the corporate governance code as per GEM listing rules, with some deviations noted[96] - The roles of Chairman and CEO are held by the same executive director, which the board believes benefits the company's business outlook[97] - The company confirmed compliance with the trading code of conduct for directors throughout the review period[98] - The company had only one independent non-executive director after the resignation of Dr. Liu Da Bei on August 3, 2023, which is below the minimum requirement of three as per GEM Listing Rule 5.05(1)[99] - The company appointed Mr. Xu Dong'an as an independent non-executive director on August 15, 2023, to comply with GEM Listing Rule 5.05A[99] - The company appointed another independent non-executive director, Mr. Xiang Bilun, on September 15, 2023, to meet the minimum requirement of three independent non-executive directors[99] - The Audit Committee consists of three independent non-executive directors, including Mr. Liu Fei as the chairman, Mr. Xu Dong'an, and Mr. Xiang Bilun[101] Staff and Employment - As of December 31, 2023, the company employed 18 staff members in Hong Kong and China, down from 19 as of June 30, 2023[70] Legal and Regulatory Matters - The company is currently negotiating with Creative Big Limited regarding a winding-up petition involving a claim of HKD 53,106,849 for the repayment of convertible bonds[49] - The hearing for the winding-up petition has been postponed to April 3, 2024, with no winding-up order issued as of the report date[72] - The company is seeking professional advice to assess the potential impact of the petition on its operations and financial condition[73] - There are no other pending winding-up petitions against the company as of the report date[73]

Financial Performance - For the six months ended December 31, 2023, the company reported revenue of HKD 18,844,000, an increase of 25.5% compared to HKD 15,025,000 for the same period in 2022[5]. - The gross profit for the six months was HKD 3,121,000, representing a slight increase of 2.7% from HKD 3,039,000 in the previous year[5]. - The company incurred a loss before tax of HKD 2,239,000, compared to a profit of HKD 15,769,000 in the same period last year, indicating a significant decline[5]. - The total comprehensive loss for the period was HKD 3,315,000, compared to a comprehensive income of HKD 13,542,000 in the previous year[7]. - The company reported a basic loss per share of HKD 0.29 for the three months ended December 31, 2023, compared to earnings per share of HKD 6.07 in the same period last year[7]. - The group reported a loss of HKD 2,239,000 for the six months ended December 31, 2023, compared to a profit of HKD 15,769,000 for the same period in 2022, indicating a significant decline in profitability[21]. - The total comprehensive loss for the period was HKD 4,151,000, compared to a total comprehensive income of HKD 13,542,000 for the same period in 2022, indicating a shift of approximately 130.7% in performance[11]. - The company reported a loss attributable to equity holders of HKD 2,876,000 for the six months ended December 31, 2023, compared to a profit of HKD 15,408,000 for the same period in 2022, representing a significant decline[34]. - The company recorded a basic and diluted loss per share of HKD 0.0156 for the six months ended December 31, 2023, compared to earnings per share of HKD 0.0849 for the same period in 2022[34]. Assets and Liabilities - The company's non-current assets amounted to HKD 9,528,000 as of December 31, 2023, an increase from HKD 6,437,000 as of June 30, 2023[8]. - Current assets increased to HKD 36,702,000 from HKD 27,045,000, primarily driven by an increase in inventory and cash[8]. - The company's total liabilities were HKD 228,739,000, up from HKD 213,236,000, reflecting an increase in trade payables[8]. - Total assets as of December 31, 2023, amounted to HKD 46,230,000, an increase from HKD 33,482,000 as of June 30, 2023[19]. - The company’s total liabilities increased slightly, with net liabilities reported at HKD 182,509,000 as of December 31, 2023, compared to HKD 179,754,000 as of June 30, 2023[10]. - The company’s total liabilities increased to HKD 112,959,000 as of December 31, 2023, compared to HKD 107,456,000 as of June 30, 2023, showing an increase of about 5.3%[40]. Cash Flow - The company reported a net cash outflow from operating activities of HKD 1,317,000 for the six months ended December 31, 2023, compared to a net cash inflow of HKD 4,720,000 for the same period in 2022, representing a significant decline in cash generation[13]. - Cash and cash equivalents at the end of the period increased to HKD 8,505,000 from HKD 7,283,000 at the end of the previous year, marking a growth of 16.7%[13]. - The company did not incur any interest payments during the six months ended December 31, 2023, compared to HKD 3,500,000 in interest payments for the same period in 2022[13]. Strategic Focus and Future Outlook - The company has not provided specific guidance for future performance but indicated ongoing efforts in product development and market expansion[6]. - The company is focusing on enhancing its operational efficiency and exploring potential strategic partnerships to drive growth[6]. - The company is focusing on the "Internet+" business and the health product sector, leveraging its supply chain service experience to explore new development opportunities[58]. - The company plans to accelerate its investment in the health industry supply chain services while reallocating resources away from personal protective equipment due to decreased market demand[57]. Share Capital and Convertible Bonds - The company issued convertible bonds with a principal amount of HKD 89,625,000 at an annual interest rate of 10%, with a conversion price adjusted to HKD 0.221 per share[46]. - The total outstanding balance of the convertible bonds at maturity was HKD 105,747,000, which includes the principal and accrued interest[46]. - The company issued a second set of convertible bonds with a principal amount of HKD 50,000,000, maturing on February 20, 2023, at an annual interest rate of 7%[47]. - The initial conversion price for the second set of convertible bonds is HKD 0.29, allowing for the issuance of up to 172,413,793 shares upon full conversion[47]. - The company’s share capital remained unchanged at HKD 57,404,000 as of December 31, 2023, consistent with the previous reporting period[11]. - The company’s share capital was consolidated on August 29, 2023, with every 25 shares of HKD 0.0125 par value consolidated into one share of HKD 0.3125[92]. Corporate Governance - The company has adopted and complied with the applicable code provisions of the GEM Listing Rules, with some deviations noted regarding the separation of the roles of Chairman and CEO[98]. - The company confirmed that all directors adhered to the trading code of conduct during the review period[100]. - The audit committee consists of three independent non-executive directors, including Mr. Liu Fei as the chairman, and has reviewed the unaudited results for the six months ending December 31, 2023[103]. - The company has complied with the GEM Listing Rules regarding the appointment of independent non-executive directors after the recent appointments[101]. Employment and Staff - The company employed 18 staff members as of December 31, 2023, down from 19 as of June 30, 2023[72].

Financial Performance - For the three months ended September 30, 2023, the company reported revenue of HKD 3,991,000, a decrease of 29.0% compared to HKD 5,627,000 for the same period in 2022[3] - The cost of sales and services for the same period was HKD 2,357,000, down from HKD 4,127,000, resulting in a gross profit of HKD 1,634,000, which is an increase of 8.9% from HKD 1,500,000[3] - The company incurred an operating loss of HKD 723,000 compared to an operating profit of HKD 6,309,000 in the previous year, indicating a significant decline in operational performance[3] - The pre-tax loss for the period was HKD 1,621,000, contrasting with a pre-tax profit of HKD 4,494,000 in the same quarter of 2022[3] - The total comprehensive loss for the period amounted to HKD 1,855,000, compared to a comprehensive income of HKD 3,985,000 in the prior year[5] - The company reported a basic loss per share of HKD 1.28, compared to earnings per share of HKD 2.41 in the same period last year[5] - Other income and gains for the quarter were nil, a significant drop from HKD 10,679,000 in the previous year, which included compensation income from the sale of locked shares[11] - The company did not report any significant government grants during the period, contrasting with HKD 311,000 received in the previous year[11] - The company reported unaudited consolidated revenue of HKD 4,000,000 for the period, a decrease of 29% compared to HKD 5,600,000 in the previous year[23] - The gross profit margin increased from 27% in the previous year to approximately 41% in the current period[23] - The net loss attributable to equity holders was HKD 2,300,000, compared to a profit of HKD 4,400,000 in the same period last year[23] - Sales and distribution expenses, along with administrative expenses, decreased by 56% to HKD 2,400,000 from HKD 5,300,000 in the previous year[23] - Financing costs decreased by 51% to HKD 900,000 from HKD 1,800,000 in the previous year[23] Business Segments and Strategy - The company’s main business segments include "Internet+" services (supply chain solutions) and manufacturing and distribution of personal protective equipment[8] - The company is focusing on the "Internet+" business model to expand its health industry supply chain services[24] - The "Internet+" business provided the main revenue source during the review period, enhancing supply chain services for health products[25] - The company has obtained relevant drug operation licenses to expand product variety and regional coverage in the health product sector[25] - Collaborations with health product brands are being established to provide comprehensive supply chain services in China and Hong Kong[25] - The health industry supply chain is a key development direction for the company, aiming to accelerate business progress through contracts with various product brands[25] - The company is focusing on expanding its business in the health industry, including production, distribution, and supply chain processes, to create new revenue sources[26] - The company plans to enhance its distribution and wholesale of health products, including traditional Chinese medicine, chemical drugs, and antibiotics, to increase market share and growth opportunities[26] - The company is conducting feasibility studies for strategic deployments across various regions in China within the health industry[26] - The company is exploring different avenues within the health industry chain to identify new business development opportunities[26] Shareholder and Governance Information - As of September 30, 2023, major shareholders include Frontend Investment Co., Ltd. with 27,097,575 shares (14.75%) and Integrated Asset Management (Asia) Limited with 21,694,520 shares (11.81%)[35] - The board of directors does not recommend the payment of dividends for the three months ending September 30, 2023[27] - As of September 30, 2023, the total number of shares held by directors and key executives amounts to 1,752,000 shares, representing 0.95% of the company[29] - The company has not engaged in any arrangements that would allow directors or key executives to benefit from purchasing shares or bonds of the company during the reporting period[33] - The company has not established any provisions for preemptive rights regarding the issuance of new shares to existing shareholders[45] - The company has adopted and complied with the applicable corporate governance code as per GEM listing rules, with some deviations noted[46] - The roles of chairman and CEO are currently held by executive directors, which the board believes benefits the group's business outlook and management[47] - The company has confirmed compliance with the trading conduct rules for directors regarding securities transactions during the three months ending September 30, 2023[48] - The audit committee consists of three independent non-executive directors, with Liu Fei as the chairman[49] - The audit committee is responsible for reviewing the company's annual reports, interim reports, and quarterly reports, providing recommendations to the board[51] - The committee has reviewed the unaudited performance for the three months ended September 30, 2023, and confirmed compliance with applicable accounting standards[51] - The board of directors includes executive directors Zhou Weihua, He Jinjian, and Guo Shuyi, along with non-executive director Cheng Yanjie and independent non-executive directors Liu Fei, Xu Dong'an, and Xiang Bilun[52] Stock Options and Bonds - The company holds a convertible bond issued in 2014 with a principal amount of HKD 89,625,000, convertible into a maximum of 405,542,986 shares at a conversion price of HKD 0.221 per share[36] - The company is in discussions with bondholders regarding the renewal or extension of the convertible bonds[36] - The company adopted a stock option plan on June 9, 2021, allowing the board to grant options to qualified individuals to incentivize and reward their contributions[39] - As of September 30, 2023, a total of 10,396,000 stock options were granted under the plan, with 9,560,000 options remaining after adjustments for cancellations[40] - The exercise price for the stock options is set at HKD 1.00, with various vesting periods extending until June 30, 2028[40] - No shares were purchased, sold, or redeemed by the company or its subsidiaries during the three months ending September 30, 2023[43] - There are no competitive interests held by directors or major shareholders in any business that directly or indirectly competes with the group as of September 30, 2023[44]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 8156) 截至二零二三年九月三十日止三個月之 第一季度業績公告 國藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本 公司及其附屬公司截至二零二三年九月三十日止三個月的未經審核綜合財務業績。本公 告列載本公司第一季度報告2023/2024的全文，並符合香港聯合交易所有限公司GEM證 券上市規則（「GEM上市規則」）中有關季度業績初步公告附載的相關資料要求。 承董事會命 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 執行董事 周偉華 香港，二零二三年十一月十四日 於本公告日期，董事會由執行董事周偉華先生、何錦堅先生及郭淑儀女士，非執行董事程彥杰 博士，以及獨立非執行董事劉斐先生、許東安先生及向碧倫先生組成。 本 ...

Business Development and Revenue - The company continues to develop its pandemic-oriented business and "Internet+" services, establishing a solid foundation for future growth[9] - "Internet+" services provided the main revenue source during the review period, with ongoing expansion into supply chain services for health products[10] - The company has successfully entered various platforms, including Douyin and Xiaodian, to offer one-stop product supply chain services[10] - Revenue from personal protective equipment (PPE) decreased due to reduced demand as the pandemic situation improved, prompting a resource reallocation towards health industry supply chain services[11] - Revenue from the "Internet+" supply chain services increased by 25% to HKD 37,100,000, compared to HKD 29,700,000 in the previous fiscal year[17] - The gross margin for "Internet+" supply chain services improved to 13%, up from 8% in the previous year[17] - Revenue from PPE decreased by 37% to HKD 5,700,000, down from HKD 9,100,000 year-on-year, with a gross margin of 12% compared to 26% previously[18] - The company is exploring new opportunities in the health industry, including production and distribution of health products, and has signed contracts with health product brands for supply chain services in China and Hong Kong[15] - The company has established a joint venture in China to develop distribution for traditional Chinese medicine and health products, which is now fully operational[15] Financial Performance - The company recorded revenue of HKD 42,800,000 for the year ended June 30, 2023, representing a 4% increase from HKD 41,000,000 in the same period of 2022[16] - Gross profit decreased to HKD 5,500,000, down 7% from HKD 5,900,000 year-on-year, primarily due to reduced income from personal protective equipment (PPE) and increased production costs[16] - The company reported a loss attributable to equity holders of HKD 10,600,000, an 88% decrease compared to a loss of HKD 88,000,000 in the previous year[16] Corporate Governance and Compliance - The company has adopted and complied with the GEM Listing Rules Appendix 15 Corporate Governance Code, with some deviations noted[43] - The roles of Chairman and CEO are currently held by executive directors, which the board believes benefits the group's business prospects and management[46] - The board is responsible for reviewing the group's financial performance and approving strategic plans, major investments, and risk management policies[49] - The company had three independent non-executive directors until May 15, 2023, but this number fell below the required minimum of three after resignations[50] - The company appointed an independent non-executive director on August 15, 2023, and another on September 15, 2023, to comply with GEM Listing Rules[50] - All independent non-executive directors have submitted annual confirmations of their independence as required by GEM Listing Rules[51] - The company provides regular updates to directors on business developments and encourages participation in relevant seminars for professional development[53] - The board of directors held a total of 9 meetings during the fiscal year ending June 30, 2023[54] - The audit committee conducted 5 meetings to review financial reporting and compliance procedures[59] - The company appointed Dr. Xu Dong'an to the audit committee on August 15, 2023, and Mr. Xiang Bilun on September 15, 2023, to comply with GEM listing rules[58] - The audit committee's main responsibilities include reviewing the company's financial information and internal control systems[59] - The company has committed to providing all relevant information to the board and committees in a timely manner[56] - The board of directors ensures compliance with all applicable rules and regulations during meetings[56] - The company has sought independent professional advice when necessary, with costs covered by the company[56] - The company has a clear structure for its board committees, including specific powers and responsibilities[57] Employee and Talent Management - The total employee cost for the year was approximately HKD 5,000,000, a significant decrease from HKD 19,000,000 in 2022, with 19 employees as of June 30, 2023, down from 32[31] - The company employed a total of 19 staff members as of June 30, 2023, with compensation policies based on performance and market trends[31] - The company has implemented internal training and development opportunities for employees, ensuring a healthy and safe work environment[83] - The company achieved a gender ratio of approximately 68% male to 32% female among staff, including senior management, as of June 30, 2023[71] - The board diversity policy was successfully implemented, achieving measurable targets including at least one director of a different gender and representation from multiple age groups[70] - The company reported zero work-related deaths and zero days lost due to work injuries for the years ending June 30, 2023, 2022, and 2021[181] - The percentage of trained employees increased for males to 26.00% in 2023 from 25.00% in 2022, while for females it rose to 5.00% from 0.00%[185] - Average training hours per employee remained at 1.00 hour for both male and female employees in 2023, consistent with 2022[186] Legal and Regulatory Issues - The company is facing uncertainties in its lottery-related business and will explore its prospects while making necessary adjustments[12] - The company is currently in negotiations regarding the extension of convertible bonds issued in 2014, with a principal amount of HKD 89,625,000, which are no longer convertible[27] - A liquidation petition was filed against the company on August 31, 2023, for the repayment of HKD 53,106,849 related to convertible bonds, with a hearing scheduled for November 15, 2023[32] - The company is actively seeking legal advice and considering all necessary actions to protect its legal rights regarding a potential court application for a confirmation order[34] - The company will keep shareholders and potential investors informed of any significant developments related to the petition and its potential adverse effects on the group's business and operations[34] - The company is facing a liquidation petition for the repayment of convertible bonds totaling HKD 53,106,849, with a court hearing scheduled for November 15, 2023[147] - The company is actively negotiating with the petitioner to seek an amicable resolution to the liquidation petition[149] Environmental and Social Responsibility - The company has implemented energy-saving measures to reduce greenhouse gas emissions, which are primarily from daily electricity consumption[157] - The company reported zero emissions of nitrogen oxides, sulfur oxides, and suspended particulate matter for the year ending June 30, 2023, compared to 2,794 grams, 9.41 grams, and 205.72 grams respectively for the previous year[158] - The company is committed to improving energy and resource efficiency to manage its greenhouse gas emissions[159] - The company has adopted responsible waste management policies to minimize waste generation and promote recycling[157] - The company recognizes the potential financial impacts of climate-related risks and is monitoring regulatory environments and product markets to ensure compliance[175] - Supplier selection is based on environmental and social standards, with regular assessments of supply chain management risks[189] Shareholder and Capital Management - The total issued share capital as of June 30, 2023, was 4,592,326,397 shares, with a recent issuance of 54,637,617 shares at a price of HKD 0.28 per share[25] - On August 25, 2023, shareholders approved a share consolidation, merging every 25 shares into 1 share with a new par value of HKD 0.3125, effective August 29, 2023[26] - The board of directors did not recommend any dividend for the year ended June 30, 2023, consistent with the previous year[87] - The company has adopted a dividend policy that considers factors such as earnings per share and financial condition[88] - The company confirmed it has maintained sufficient public float as per GEM listing rules[94] - The company has not purchased, sold, or redeemed any listed securities during the year ended June 30, 2023[101] Stock Options and Incentives - The company granted a total of 263,900,000 share options at an exercise price of HKD 0.04, effective from July 1, 2023, to June 30, 2028[141] - The total number of stock options granted under the old stock option plan is 178,850,000[128] - The exercise price for the stock options is set at HKD 0.33[128] - The total number of stock options outstanding as of June 30, 2023, for the top five individuals was 60,100,000 shares[136] - The total number of stock options outstanding as of June 30, 2023, for other grantees was 96,650,000 shares[136] - The stock options granted to directors include a total of 128,900,000, with a significant portion still available for future exercise[137] - The company has granted stock options to multiple directors and employees, with significant allocations to key personnel[128] - The stock options are part of the company's strategy to incentivize and retain talent[128] Market and Customer Relations - Sales to the top five customers accounted for approximately 61% of total sales, with the largest customer representing about 33%[85] - Purchases from the top five suppliers constituted around 86% of total procurement, with the largest supplier accounting for 59%[85] - The company has maintained a cooperative relationship with suppliers to effectively meet customer demands[84] - The company received no written complaints regarding product and service quality during the year, and has procedures in place to investigate and address any complaints[196] Risk Management - The company faced risks related to the "Internet+" service business, which is influenced by industry trends and future developments[82] - Demand for personal protective equipment (PPE) was directly affected by community health measures and the severity of the pandemic, impacting production and distribution[82] - The company incurred costs due to material, transportation, and labor law changes, which may affect profit margins in its "Internet+" services and PPE manufacturing[82] - The company is focused on expanding its market presence through innovative product development and strategic partnerships[138]